Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches

Vascular endothelial growth factor receptor-2, (VEGFR-2), is a key element in angiogenesis, the process by which new blood vessels are formed, and is thus an important pharmaceutical target. Here, 3-D quantitative structure–activity relationship (3-D QSAR) were used to build a quantitative screening and pharmacophore model of the VEGFR-2 receptors for design of inhibitors with improved activities. Most of available experimental data information has been used as training set to derive optimized and fully cross-validated eight mono-probe and a multi-probe quantitative models. Notable is the use of 262 molecules, aligned following both structure-based and ligand-based protocols, as external test set confirming the 3-D QSAR models’ predictive capability and their usefulness in design new VEGFR-2 inhibitors. From a survey on literature, this is the first generation of a wide-ranging computational medicinal chemistry application on VEGFR2 inhibitors.

[1]  R. Costi,et al.  Pharmacophore Assessment Through 3-D QSAR: Evaluation of the Predictive Ability on New Derivatives by the Application on a Series of Antitubercular Agents , 2013, J. Chem. Inf. Model..

[2]  O. Silakari,et al.  3D-QSAR Studies of Various Diaryl Urea Derivatives of Multi-targeted Receptor Tyrosine Kinase Inhibitors: Molecular Field Analysis Approach , 2008 .

[3]  Huanxiang Liu,et al.  Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. , 2009, Journal of molecular graphics & modelling.

[4]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[5]  Mark S. Johnson,et al.  ShaEP: Molecular Overlay Based on Shape and Electrostatic Potential , 2009, J. Chem. Inf. Model..

[6]  Haichun Liu,et al.  De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction , 2012, Molecular Diversity.

[7]  Fabrizio Manetti,et al.  HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. , 2005, Journal of medicinal chemistry.

[8]  R. Hartmann,et al.  CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. , 2008, Bioorganic & medicinal chemistry.

[9]  Huabei Zhang,et al.  Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors. , 2010, Journal of molecular graphics & modelling.

[10]  Wang Zan,et al.  Pharmacophore-based 3D-QSAR as a predictive method for the QSAR analysis on a series of potent and selective inhibitors for three kinases of RTK family , 2010 .

[11]  P. A. Harris,et al.  Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. , 2008, Journal of medicinal chemistry.

[12]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Da Settimo,et al.  Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). , 2013, European journal of medicinal chemistry.

[14]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.

[15]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[16]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[17]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[18]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[19]  E. Hu,et al.  Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit. , 2008, Journal of medicinal chemistry.

[20]  Mark S. Johnson,et al.  Generating Conformer Ensembles Using a Multiobjective Genetic Algorithm , 2007, J. Chem. Inf. Model..

[21]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[22]  N. Ferrara,et al.  Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.

[23]  Yadong Chen,et al.  Pharmacophore Guided 3D‐QSAR CoMFA Analysis of Amino Substituted Nitrogen Heterocycle Ureas as KDR Inhibitors , 2009 .

[24]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[25]  Bikash R. Sahoo,et al.  Exploring novel KDR inhibitors based on pharmaco-informatics methodology , 2013, SAR and QSAR in environmental research.

[26]  Antonia Caroli,et al.  Hsp90 Inhibitors, Part 1: Definition of 3-D QSAutogrid/R Models as a Tool for Virtual Screening , 2014, J. Chem. Inf. Model..

[27]  Shuguang Wu,et al.  Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors , 2012, Journal of Molecular Modeling.

[28]  S. Wold,et al.  PLS: Partial Least Squares Projections to Latent Structures , 1993 .

[29]  R. Raychowdhury,et al.  Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.

[30]  M. Rajagopalan,et al.  Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors , 2013, Journal of enzyme inhibition and medicinal chemistry.

[31]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[32]  M. Morrison,et al.  Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. , 2008, Journal of medicinal chemistry.

[33]  T. Ng,et al.  A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  P. Depreux,et al.  Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[35]  Neerja Kaushik-Basu,et al.  Combining 3-D Quantitative Structure-Activity Relationship with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors , 2010, J. Chem. Inf. Model..

[36]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[37]  Mark S. Johnson,et al.  Accurate conformation‐dependent molecular electrostatic potentials for high‐throughput in silico drug discovery , 2009, J. Comput. Chem..

[38]  Taebo Sim,et al.  Pharmacophore based 3D-QSAR study of VEGFR-2 inhibitors , 2009, Medicinal Chemistry Research.

[39]  S. Rafii,et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.

[40]  Federico Corelli,et al.  Hsp90 Inhibitors, Part 2: Combining Ligand-Based and Structure-Based Approaches for Virtual Screening Application , 2014, J. Chem. Inf. Model..

[41]  Jans H. Alzate-Morales,et al.  Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. , 2012, Journal of molecular graphics & modelling.

[42]  P. Lan,et al.  Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR , 2011, Journal of enzyme inhibition and medicinal chemistry.

[43]  Yutaka Maeda,et al.  Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[44]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[45]  P. Singh,et al.  A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRα tyrosine kinase inhibitors: Derivatives of N-Phenyl-N′-{4-(4-quinolyloxy)phenyl}urea as antitumor agents , 2008, Journal of enzyme inhibition and medicinal chemistry.

[46]  Elizabeth Yuriev,et al.  Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.

[47]  S. Cho,et al.  Pharmacophore and docking-based combined in-silico study of KDR inhibitors. , 2009, Journal of molecular graphics & modelling.

[48]  T. Bhat,et al.  The Protein Data Bank and the challenge of structural genomics , 2000, Nature Structural Biology.

[49]  Yuquan Wei,et al.  YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models , 2014, Scientific Reports.

[50]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[51]  Ajay N. Jain,et al.  Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.

[52]  Rino Ragno,et al.  3-D QSAutogrid/R: An Alternative Procedure To Build 3-D QSAR Models. Methodologies and Applications , 2012, J. Chem. Inf. Model..

[53]  Richard Kendall,et al.  Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.